Asset profile
risankizumab · Skyrizi
Monoclonal antibody
Evidence outlook
Approved: Psoriasis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response to, lost response to, or...), Psoriatic Arthritis, Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
155 competitors in this universe: 14 direct rivals (same mechanism and indication), 0 same-class, 141 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Risankizumab (Skyrizi): this drug | Approved | Monoclonal antibody | IL-23 p19 | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Ustekinumab-Stba (Steqeyma) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| HS-20137 | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | ||
| Picankibart | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| ORKA-001 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SHR-1139 | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor | ||
| SPY003 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SOR102 | Phase 1 | Biologic (subtype unspecified) | TNF-alpha, IL-23 p19 | ||
| TL-003 | Phase 1 | Multispecific antibody | TL1A, IL-23 p19 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells |
…and 140 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
8 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (6)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
2028 (6)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
September 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (2)
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2034 (1)
July 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.